Search Result
Results for "
circulates
" in MedChemExpress (MCE) Product Catalog:
2
Biochemical Assay Reagents
8
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-70002AS
-
|
N-desmethyl MDV 3100-d6
|
Androgen Receptor
|
Cancer
|
|
N-desmethyl Enzalutamide-d6 is a deuterium labeled N-desmethyl Enzalutamide. N-desmethyl Enzalutamide is an active metabolite of Enzalutamide. N-desmethyl Enzalutamide is the active metabolite of Enzalutamide. N-desmethyl Enzalutamide demonstrates primary and secondary pharmacodynamics of similar potency to Enzalutamide and circulates at approximately the same plasma concentrations as enzalutamide[1].
|
-
-
- HY-113046
-
|
5-Methyl THF; 5-MTHF
|
Endogenous Metabolite
|
Cardiovascular Disease
Metabolic Disease
|
|
5-Methyltetrahydrofolic acid (5-Methyl THF) is the main circulating form of folic acid in the body and is involved in a variety of biochemical reactions. 5-Methyltetrahydrofolic acid regulates cardiovascular function by increasing the production of endothelin-1 (ET-1) in low-density lipoprotein-treated endothelial cells and can be used in the study of cardiovascular diseases .
|
-
-
- HY-135334
-
|
|
Drug Metabolite
Btk
Cytochrome P450
|
Cancer
|
|
ACP-5862 is a major active, circulating, pyrrolidine ring-opened metabolite of Acalabrutinib with an IC50 of 5.0 nM for Bruton tyrosine kinase (BTK). ACP‐5862 is a weak time‐dependent inactivator of CYP3A4 and CYP2C8. Acalabrutinib is an orally active, irreversible, and highly selective BTK inhibitor, with an IC50 of 3 nM and EC50 of 8 nM .
|
-
-
- HY-145668
-
|
|
Others
|
Cancer
|
|
Cyclopentenyl uracil, a non-cytotoxic inhibitor of uridine kinase, effectively blocks the salvage of circulating uridine by host and tumor tissues in the intact mouse .
|
-
-
- HY-13332
-
|
25-hydroxy Vitamin D3-d6
|
VD/VDR
|
Metabolic Disease
|
|
Calcifediol-d6 is the deuterium labeled Calcifediol. Calcifediol, a major circulating metabolite of vitamin D3, is a potent VDR ligand .
|
-
-
- HY-100652A
-
|
|
Factor Xa
|
Cardiovascular Disease
|
|
O-Desmethyl apixaban sulfate sodium is a major circulating metabolite of Apixaban in humans. O-Desmethyl apixaban sulfate sodium inhibits factor X (FXa) with a Ki of 58 μM .
|
-
-
- HY-117229
-
|
|
Drug Metabolite
|
Cancer
|
|
Sonidegib metabolite M48 is the main circulating metabolite of Sonidegib. Sonidegib is a hedgehog pathway inhibitor. M48 showed a much longer Tmax (60 h) than Sonidegib .
|
-
-
- HY-113488
-
|
|
Others
|
Endocrinology
|
|
8,9-Epoxyeicosatrienoic acid has an unique protective effect on glomeruli. 8,9-Epoxyeicosatrienoic acid blocks the increase in glomerular albumin permeability caused by circulating permeability factor (FSPF). 8,9-Epoxyeicosatrienoic acid can be used for the research of glomerular dysfunction .
|
-
-
- HY-124099
-
|
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
SCH 40120 is a potent leukotriene inhibitor with antiinflammatory effects. SCH 40120 suppresses T cell proliferative responses, antigen-specific and poly-clonally-induced in vitro antibody responses. SCH 40120 suppresses an edematous response and inhibits the recruitment of circulating neutrophils into sites of inflammation. SCH 40120 is proming for rasearch of anti-psoriatic agents .
|
-
-
- HY-130272
-
|
|
Others
|
Cardiovascular Disease
|
|
Anti-MI/R injury agent 1 (compound 18), a Panaxatriol derivative, is an orally active, potent anti-myocardial ischemia/reperfusion (anti-MI/R) injury agent. Anti-MI/R injury agent 1 enhances oxygen-glucose deprivation and reperfusion (OGD/R)-induced cardiomyocyte injury cell viability. Anti-MI/R injury agent 1 can markedly reduce myocardial infarction size, decrease circulating cardiac troponin I (cTnI) leakage, and alleviate cardiac tissue damage in the rats .
|
-
-
- HY-114297
-
|
|
Endogenous Metabolite
|
Others
|
|
Zymosterol is a Cholesterol (HY-N0322) biosynthesis metabolite. Zymosterol, a precursor of Cholesterol, is found mostly in the plasma membrane. Zymosterol circulates within the cell .
|
-
-
- HY-159007
-
|
R,S-1,3-Butanediol acetoacetate diester
|
Others
|
Cardiovascular Disease
Metabolic Disease
|
|
BD-AcAc2 is an orally active antiepileptic. BD-AcAc2 results in body weight loss or maintenance with moderate increases in circulating ketones .
|
-
-
- HY-119244
-
|
|
Dipeptidyl Peptidase
|
Others
|
|
Gly-Pro-pNA hydrochloride is a chromogenic substrate that can be cleaved by the circulating enzyme, dipeptidyl peptidase IV (DPP IV). Gly-Pro-pNA can be used to screen for DPP IV inhibitors .
|
-
-
- HY-P1573
-
-
-
- HY-P2469
-
-
-
- HY-P1573A
-
-
-
- HY-125053A
-
|
|
Glycoprotein VI
|
Cardiovascular Disease
|
|
Batifiban TFA, a cyclic peptide, is an antagonist of platelet glycoprotein GPⅡb/Ⅲa and inhibits platelet aggregation. Batifiban blocks the binding of circulating vitronectin to integrin ανβ3 .
|
-
-
- HY-W401407
-
|
|
Drug Metabolite
Cytochrome P450
|
Metabolic Disease
|
|
Diosmetin-3-O-glucuronide is a major circulating metabolite of Diosmetin (HY-N0125) in plasma and in urine. Diosmetin is a natural flavonoid which inhibits human CYP1A enzyme activity .
|
-
-
- HY-P1236
-
|
Atrial natriuretic factor (1-28) (rat, mouse)
|
Endothelin Receptor
|
Cardiovascular Disease
Endocrinology
|
|
Atrial Natriuretic Peptide (ANP) (1-28), rat, mouse is a major circulating form of ANP in rats, potently inhibits Angiotensin II (Ang II)-stimulated endothelin-1 secretion in a concentration-dependent manner.
|
-
-
- HY-150254A
-
-
-
- HY-150254
-
-
-
- HY-148370A
-
|
RG6299 sodium
|
Complement System
|
Others
|
|
IONIS-FB-LRx sodium is a specific antisense oligonucleotide (ASO) targeting complement factor B (CFB). IONIS-FB-LRx sodium effectively reduces circulating levels of CFB, and can be used for geographic atrophy (GA) research .
|
-
-
- HY-124863A
-
|
|
SphK
|
Inflammation/Immunology
|
|
(R)-AAL is an immunomodulator. (R)-AAL decreases circulating T lymphocytes in rats, with an ID50 value of 0.009 mg/kg. (R)-AAL is a substrate of sphingosine kinase (SphK), which catalyzes the phosphorylation of (R)-AAL .
|
-
-
- HY-P1236A
-
|
Atrial natriuretic factor (1-28) (rat, mouse) TFA
|
Endothelin Receptor
|
Cardiovascular Disease
Endocrinology
|
|
Atrial Natriuretic Peptide (ANP) (1-28), rat, mouse (TFA) is a major circulating form of ANP in rats, potently inhibits Angiotensin II (Ang II)-stimulated endothelin-1 secretion in a concentration-dependent manner.
|
-
-
- HY-113293B
-
|
|
Estrogen Receptor/ERR
Endogenous Metabolite
|
Cancer
|
|
Estrone sulfate, a biologically inactive form of estrogen, is a major circulating plasma estrogen that is converted into the biologically active estrogen, estrone (E1) by steroid sulfatase (STS). Estrone sulfate can be used for the research of breast cancer .
|
-
-
- HY-70002A
-
|
N-desmethyl MDV 3100
|
Androgen Receptor
|
Cancer
|
|
N-desmethyl Enzalutamide is the active metabolite of Enzalutamide.N-desmethyl Enzalutamide is the active metabolite of Enzalutamide. N-desmethyl Enzalutamide demonstrates primary and secondary pharmacodynamics of similar potency to Enzalutamide and circulates at approximately the same plasma concentrations as enzalutamide .
|
-
-
- HY-124416
-
|
|
CCR
|
Inflammation/Immunology
Endocrinology
|
|
ML604086 is a selective CCR8 inhibitor, inhibiting CCL1 binding to CCR8 on circulating T-cells. ML604086 inhibits CCL1 mediated chemotaxis and increases in intracellular Ca 2+ concentrations .
|
-
-
- HY-W440831
-
|
|
Biochemical Assay Reagents
Liposome
|
Others
|
|
DSPE-PEG-Azide, MW 1000 is a phospholipid with covalently attached polydisperse PEG. This polymer is commonly used for the preparation of long circulating liposomes. The azide moiety is reactive with alkyne to form a stable triazole bond. Reagent grade, for research use only.
|
-
-
- HY-119064
-
|
|
HMG-CoA Reductase (HMGCR)
|
Neurological Disease
|
|
L-645164 is a potent inhibitor of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase. L-645164 produces substantial decreases in circulating serum cholesterol concentrations in dogs. L-645164 is promising for research of central nervous system disorders .
|
-
-
- HY-12753S
-
|
SR35021-d7
|
Isotope-Labeled Compounds
Drug Metabolite
|
Cardiovascular Disease
|
|
Debutyldronedarone-d7 is deuterium labeled Debutyldronedarone. Debutyldronedarone is a major circulating active metabolite of dronedarone (HY-A0016) in humans.Debutyldronedarone exhibits a potency that is 1/10 to 1/3 of that of the parent agent[1][2].
|
-
-
- HY-12753S1
-
|
SR35021-dd6 hydrochloride
|
Isotope-Labeled Compounds
Drug Metabolite
|
Cardiovascular Disease
|
|
Debutyldronedarone-d6 (hydrochloride) is deuterium labeled Debutyldronedarone. Debutyldronedarone is a major circulating active metabolite of dronedarone (HY-A0016) in humans. Debutyldronedarone exhibits a potency that is 1/10 to 1/3 of that of the parent agent[1][2].
|
-
-
- HY-148370
-
|
RG6299
|
Complement System
|
Others
|
|
IONIS-FB-LRx is a specific antisense oligonucleotide (ASO) targeting complement factor B (CFB). IONIS-FB-LRx effectively reduces circulating levels of CFB. IONIS-FB-LRx can be used for geographic atrophy (GA) research .
|
-
-
- HY-P99645
-
-
-
- HY-125053
-
|
|
Integrin
|
Cardiovascular Disease
|
|
Batifiban, a cyclic peptide, is a platelet glycoprotein GPⅡb/Ⅲa antagonist, and inhibits platelet aggregation. Batifiban blocks circulating vitronectin binding to integrin ανβ3, Batifiban can be used for research of acute coronary syndromes .
|
-
-
- HY-P99790
-
|
CEN 000029; cM-T412
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Priliximab (CEN 000029) is an anti-CD4 humanized monoclonal antibody. Priliximab binds to CD4 on the surface of T cells, resulting in a significant and sustained reduction in circulating CD4 + T cells. Priliximab can be used in research of rheumatoid arthritis (RA) .
|
-
-
- HY-158093
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
NIC-12 is a potent NLRP3 inhibitor. NIC-12 selectively reduces circulating IL-1ß levels in the LPS-endotoxemia mice model. NIC-12 inhibits NLRP3 inflammasome activation in mouse macrophages .
|
-
-
- HY-126044
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
6-Hydroxy bexarotene is the main circulating metabolite of bexarotene, found in rats, dogs, and humans. Compared to the parent compound, 6-hydroxy-bexarotene shows a significantly reduced ability to bind to retinoid receptors and exhibits very minimal activity in activating retinoic acid receptors .
|
-
-
- HY-108860
-
|
PEG-L-asparaginase; Pegasparaginase
|
FGFR
Interleukin Related
|
Inflammation/Immunology
|
|
Oncaspar (PEG-L-asparaginase; Pegasparaginase), a pegylated form of native Escherichia coli-derived L-asparaginase, breaks down the amino acid asparagine that are circulating in the bloodstream. Oncaspar plays an important role in acute lymphoblastic leukemia (ALL) through asparagine hydrolysis and activation of the integrated stress response (ISR) pathway .
|
-
-
- HY-E70524
-
|
|
PAI-1
|
Cardiovascular Disease
|
|
Alpha 2 Antiplasmin, Human Plasma is Alpha-2 antiplasmin from human plasma. Alpha-2 antiplasmin is the major circulating inhibitor of plasmin. Alpha-2 antiplasmin plays a determining role in the regulation of intravascular fibrinolysis .
|
-
-
- HY-153485
-
|
ISIS 766720; IONIS-GHR-LRx
|
GHR
Small Interfering RNA (siRNA)
|
Others
|
|
Cimdelirsen is a novel, ligand-conjugated, hepatic-targeted investigative antisense oligonucleotide designed to reduce growth hormone receptor (GHr) synthesis, thereby inhibiting deleterious effects of growth hormone (GH) hypersecretion and reducing circulating insulin-like growth factor-1 (IGF-1) levels in acromegaly patients.
|
-
-
- HY-162655A
-
|
|
LPL Receptor
|
Inflammation/Immunology
|
|
SLF80821178 hydrochloride is an orally active inhibitor for sphingosine-1-phosphate transporter (Spns2), that inhibits the sphingosine-1-phosphate (S1P) release in HeLa with an IC50 of 51 nM. SLF80821178 hydrochloride reduces the circulating lymphocyte without affecting plasma S1P levels in mice .
|
-
-
- HY-153485A
-
|
ISIS 766720 sodium; IONIS-GHR-LRx sodium
|
GHR
Small Interfering RNA (siRNA)
|
Others
|
|
Cimdelirsen is a novel, ligand-conjugated, hepatic-targeted investigative antisense oligonucleotide designed to reduce growth hormone receptor (GHr) synthesis, thereby inhibiting deleterious effects of growth hormone (GH) hypersecretion and reducing circulating insulin-like growth factor-1 (IGF-1) levels in acromegaly patients.
|
-
-
- HY-113293BS
-
|
|
Estrogen Receptor/ERR
Endogenous Metabolite
|
Cancer
|
|
Estrone sulfate-d5 (sodium) is the deuterium labeled Estrone sulfate sodium. Estrone sulfate, a biologically inactive form of estrogen, is a major circulating plasma estrogen that is converted into the biologically active estrogen, estrone (E1) by steroid sulfatase (STS). strone sulfate can be used for the research of breast cancer[1][2].
|
-
-
- HY-113293BS1
-
|
|
Estrogen Receptor/ERR
Endogenous Metabolite
|
Cancer
|
|
Estrone sulfate-d4 (sodium) is deuterium labeled Estrone sulfate (sodium). Estrone sulfate, a biologically inactive form of estrogen, is a major circulating plasma estrogen that is converted into the biologically active estrogen, estrone (E1) by steroid sulfatase (STS). strone sulfate can be used for the research of breast cancer[1][2].
|
-
-
- HY-110197
-
6bK TFA
1 Publications Verification
|
Insulin Receptor
|
Metabolic Disease
|
|
6bK TFA is a potent and selective insulin degrading enzyme (IDE) inhibitor with an IC50 value of 50 nM. 6bK TFA increases circulating insulin in high-fat-fed mice. Acute administration of 6bK TFA enhances glucose tolerance to oral glucose, notably to a greater extent in high-fat-fed mice .
|
-
-
- HY-P99443
-
|
HuDreg-55
|
P-selectin
|
Inflammation/Immunology
|
|
Aselizumab (HuDreg-55) is an humanized IgG4 mAb against L-selectin. However, L-selectin (CD62L) is a cell adhesion molecule expressed on circulating neutrophils. It regulates migrating cells to chemotaxis towards the site of injury. Aselizumab may be account for a high rate of infections and leucopenia after truma .
|
-
-
- HY-100658
-
|
|
5-HT Receptor
Dopamine Receptor
|
Neurological Disease
|
|
Didesmethyl cariprazine is a metabolite of Cariprazine and acts as the predominant circulating active moiety. Didesmethyl cariprazine has a long half-life of 1-3 weeks. Cariprazine is a antipsychotic agent candidate that exhibits high affinity for the D3 and D2 receptors, and moderate affinity for the 5-HT1A receptor .
|
-
-
- HY-165393
-
|
N-(9E)-9-Octadecen-1-ylsulfamide
|
PPAR
|
Metabolic Disease
|
|
Elaidyl-sulfamide (N-(9E)-9-Octadecen-1-ylsulfamide) is a PPARα agonist. Elaidyl-sulfamide reduces body weight gain and food intake and reduces circulating cholesterol levels and increases both glucose and insulin levels. Elaidyl-sulfamide has the potential for the research of complicated obesity .
|
-
-
- HY-W747868
-
|
|
HIF/HIF Prolyl-Hydroxylase
|
Cardiovascular Disease
|
|
Molidustat sodium is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with IC50 values of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD3, respectively. Molidustat sodium can elevate the levels of circulating erythropoietin (EPO) to near-normal physiological ranges. Molidustat sodium can be utilized in the research of renal anemia .
|
-
-
- HY-139230
-
|
|
Cannabinoid Receptor
PPAR
|
Metabolic Disease
|
|
OLHHA is a dual CB1 receptor antagonist and PPARα agonist. OLHHA also is a alcohol intake inhibitor with an EC50 value of 0.2 mg/kg. OLHHA reduces both hepatic lipid accumulation and circulating triglyceride levels. OLHHA shows anti-steatotic activity and has the potential for the research of non-alcoholic fatty liver disease (NAFLD) .
|
-
- HY-12654
-
|
BAY 85-3934
|
HIF/HIF Prolyl-Hydroxylase
|
Cardiovascular Disease
|
|
Molidustat (BAY 85-3934) is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with IC50 values of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD3, respectively. Molidustat can elevate the levels of circulating erythropoietin (EPO) to near-normal physiological ranges. Molidustat can be utilized in the research of renal anemia .
|
-
- HY-113046R
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
Metabolic Disease
|
|
Alisol C 23-acetate (Standard) is the analytical standard of Alisol C 23-acetate. This product is intended for research and analytical applications. Alisol C 23-acetate is a natural product extracted from Alisma orientale, which can significantly reduce delayed-type hypersensitivity reactions.
|
-
- HY-141749B
-
|
CLPM hydrochloride; SR 26334 hydrochloride
|
Drug Metabolite
|
Cardiovascular Disease
|
|
Clopidogrel carboxylic acid (CLPM) hydrochloride is an inactive metabolite of the widely used antiplatelet medication clopidogrel, which serves as a reference standard for quantitative analysis of clopidogrel metabolism. Clopidogrel carboxylic acid hydrochloride has been shown to represent approximately 85% of circulating clopidogrel, hydrolyzed from the active form by esterases. Clopidogrel carboxylic acid hydrochloride plays a crucial role in assessing the pharmacokinetics and bioavailability of clopidogrel in various clinical and research settings.
|
-
- HY-163480
-
|
|
CXCR
|
Inflammation/Immunology
|
|
PF-06835375 is a humanized IgG1 antibody selective against CXCR5 expressed on B cells, Tfh cells, and circulating Tfh-like (cTfh) cells. PF-06835375 can be used for the study of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) [1].
|
-
- HY-13224
-
|
|
Kinesin
Apoptosis
Mitosis
|
Cancer
|
|
AZD4877 is another isostere to Ispinesib (HY-50759)and also a kinesin spindle protein (Eg5) inhibitor with IC50 of 2 nM.AZD4877 arrests cell mitosis, leads to the formation of the monopolar spindle phenotype and induces apoptosis. AZD4877 inhibits circulating peripheral blood mononuclear cells (PBMCs) and has anti-cancer activity .
|
-
- HY-134495
-
|
N-Acetylcysteine ethyl ester; NACET
|
Reactive Oxygen Species
|
Metabolic Disease
|
|
N-Acetyl-L-cysteine ethyl ester is an esterified form of N-acetyl-L-cysteine (NAC). N-Acetyl-L-cysteine ethyl ester exhibits enhanced cell permeability, and produce NAC and cysteine. N-Acetyl-L-cysteine ethyl ester increases circulating hydrogen sulfide (H2S) and can be used as an H2S producer. N-Acetyl-L-cysteine ethyl ester has the potential to substitute NAC as a mucolytic agent, and as a GSH-related antioxidant .
|
-
- HY-P3954
-
|
|
Somatostatin Receptor
|
Metabolic Disease
|
|
Somatostatin-28 (sheep, human rat mouse) is a biologically active polypeptide, synthesised in the proximal intestinal epithelial cells. Somatostatin-28 (sheep, human rat mouse) suppresses glucose-stimulated insulin secretion without affecting circulating basal insulin concentration. Somatostatin-28 (sheep, human rat mouse) also targets to somatostatin receptor subtype 5 (SSTR5) to regulate GLP-1 secretion .
|
-
- HY-P991073
-
|
|
Amyloid-β
|
Neurological Disease
|
|
MEDI-1814 is a fully human IgG1 antibody that targets the C terminus of Aβ42. MEDI-1814 binds to and sweeps away the circulated Aβ peptides, hence, restricting them from aggregating into toxic oligomers. MEDI-1814 can be used for the study of Alzheimer's diseases. The isotype control for MEDI-1814 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-50859
-
|
INCB018424 sulfate
|
JAK
Autophagy
|
Cancer
|
|
Ruxolitinib sulfate (INCB018424 sulfate) is the first potent, selective JAK1/2 inhibitor to enter the clinic with IC50s of 3.3 nM/2.8 nM, and has > 130-fold selectivity for JAK1/2 versus JAK3.
|
-
- HY-119221A
-
|
|
LPL Receptor
|
Neurological Disease
|
|
AUY 954 hydrochloride is a potent and selective sphingosine-1-phosphate (S1P(1)) receptor agonist, exhibiting significant immunomodulatory activity. AUY 954 hydrochloride induces a profound and reversible reduction of circulating lymphocytes upon oral administration. AUY 954 hydrochloride has demonstrated efficacy in prolonging cardiac allograft survival when used in combination with RAD001 in a stringent transplantation model. AUY 954 hydrochloride effectively prevents experimental autoimmune neuritis in rats, showcasing its therapeutic potential in autoimmune conditions.
|
-
- HY-135334S
-
|
|
Isotope-Labeled Compounds
Drug Metabolite
Btk
Cytochrome P450
|
Cancer
|
|
ACP-5862-d4 is deuterium labeled ACP-5862. ACP-5862 is a major active, circulating, pyrrolidine ring-opened metabolite of Acalabrutinib with an IC50 of 5.0 nM for Bruton tyrosine kinase (BTK). ACP‐5862 is a weak time‐dependent inactivator of CYP3A4 and CYP2C8. Acalabrutinib is an orally active, irreversible, and highly selective BTK inhibitor, with an IC50 of 3 nM and EC50 of 8 nM[1][2].
|
-
- HY-113046S1
-
|
5-Methyl THF-13C6; 5-MTHF-13C6
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Cardiovascular Disease
Metabolic Disease
|
|
5-Methyltetrahydrofolic acid- 13C6 (5-Methyl THF- 13C6) is 13C labeled 5-Methyltetrahydrofolic acid. 5-Methyltetrahydrofolic acid (5-Methyl THF) is the main circulating form of folic acid in the body and is involved in a variety of biochemical reactions. 5-Methyltetrahydrofolic acid regulates cardiovascular function by increasing the production of endothelin-1 (ET-1) in low-density lipoprotein-treated endothelial cells and can be used in the study of cardiovascular diseases .
|
-
- HY-149004A
-
|
|
LPL Receptor
|
Inflammation/Immunology
|
|
SLF1081851 (TFA) is a Spns2 inhibitor, inhibits S1P release (IC50=1.93 μM). SLF1081851 (TFA) plays a key role in development and immune system .
|
-
- HY-B2097
-
|
YM 175; Bisphonal
|
Farnesyl Transferase
|
Metabolic Disease
|
|
Incadronate disodium (YM 175) is a bisphosphonate with strong inhibitory activity on bone resorption. Incadronate disodium indirectly stimulates renal 25-hydroxyvitamin D-1-hydroxylase by increasing circulating parathyroid hormone. Incadronate disodium, a cholesterol-lowering agent, is a potent inhibitor of rat liver microsomal squalene synthase (Ki=57 nM). Incadronate disodium inhibits sterol biosynthesis in mouse macrophage J774 cells (IC50=64 μM). Incadronate disodium has the potential for malignant tumors research .
|
-
- HY-123801A
-
|
GL-II-93 sodium
|
GABA Receptor
|
Inflammation/Immunology
|
|
MIDD0301 (GL-II-93) is an orally available, active γ-aminobutyric acid type A receptor (GABAAR) inhibitor and anti-asthmatic agent. MIDD0301 exhibits biological and immunotoxicological safety in mice and does not affect the number of circulating lymphocytes, monocytes, and granulocytes. MIDD0301 has no significant adverse immune response at repeated doses, which is better than Prednisone (HY-B0214). MIDD0301 relaxes histamine-contracted guinea pig and human airway smooth muscle and is used in the study of bronchoconstrictive diseases .
|
-
- HY-123801
-
|
GL-II-93
|
GABA Receptor
|
Inflammation/Immunology
|
|
MIDD0301 (GL-II-93) is an orally available, active γ-aminobutyric acid type A receptor (GABAAR) inhibitor and anti-asthmatic agent. MIDD0301 exhibits biological and immunotoxicological safety in mice and does not affect the number of circulating lymphocytes, monocytes, and granulocytes. MIDD0301 has no significant adverse immune response at repeated doses, which is better than Prednisone (HY-B0214). MIDD0301 relaxes histamine-contracted guinea pig and human airway smooth muscle and is used in the study of bronchoconstrictive diseases .
|
-
- HY-P9930
-
|
AMG 145
|
NF-κB
Ser/Thr Protease
Toll-like Receptor (TLR)
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H2O2-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .
|
-
- HY-P10065
-
-
- HY-125864
-
|
|
Interleukin Related
NF-κB
|
Inflammation/Immunology
|
|
Fibrinogen (Bovine) is a selective proteolytic molecule that can be activated by thrombin to assemble fibrin clots. Fibrinogen can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 and MCP-1. Fibrinogen plays a key role in blood clotting, thrombosis, atherosclerosis and the pathological development of venous grafts, and can be used in the study of blood clotting and vascular diseases .
|
-
- HY-126969
-
|
|
PPAR
|
Metabolic Disease
|
|
C333H is a selective PPARγ modulator with insulin-sensitizing and hypoglycemic activities. C333H exhibits similar insulin-sensitizing effects to thiazolidinediones (TZDs) in diabetic mouse models without significantly increasing body weight or adipose tissue weight. C333H increases circulating high molecular weight adiponectin isoform levels in diabetic db/db mice, reduces serine phosphorylation of PPARγ 273 in brown adipose tissue, and selectively modulates the expression of specific PPARγ target genes in adipose tissue. Express. C333H exhibits weak recruitment of co-activators and weak dissociation of co-repressors in vitro. These properties suggest that C333H may be a potential inhibitor of type 2 diabetes .
|
-
- HY-N3021
-
|
|
Endogenous Metabolite
NF-κB
TNF Receptor
FOXO
Microtubule/Tubulin
|
Metabolic Disease
|
|
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome .
|
-
-
-
HY-L182
-
|
|
298 compounds
|
|
Fatty acids (FAs) are the main components of lipids. The synthesis of fatty acids mainly involves the Triglyceride (TG) cycle and De Novo Lipogenesis (DNL). Fatty acids which exist widely in organisms are components of cell membranes and play an indispensable role in cell signaling. In addition, FFAs can be taken up from circulating plasma by all mitochondria-containing cells, and they are metabolized by β-oxidation and the citric acid cycle to release large amounts of energy in the form of ATP. Abnormal fatty acid metabolism is associated with the occurrence and development of cardiovascular diseases, diabetes, fatty liver, hyperthyroidism, and other diseases.
MCE offers a unique collection of fatty acid compounds. Fatty Acids Compound Library is an important tool for the study of energy metabolism and drug development of metabolism-related diseases.
|
| Cat. No. |
Product Name |
Type |
-
- HY-125864
-
|
|
Native Proteins
|
|
Fibrinogen (Bovine) is a selective proteolytic molecule that can be activated by thrombin to assemble fibrin clots. Fibrinogen can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 and MCP-1. Fibrinogen plays a key role in blood clotting, thrombosis, atherosclerosis and the pathological development of venous grafts, and can be used in the study of blood clotting and vascular diseases .
|
-
- HY-W440831
-
|
|
Drug Delivery
|
|
DSPE-PEG-Azide, MW 1000 is a phospholipid with covalently attached polydisperse PEG. This polymer is commonly used for the preparation of long circulating liposomes. The azide moiety is reactive with alkyne to form a stable triazole bond. Reagent grade, for research use only.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P2469
-
-
- HY-125053A
-
|
|
Glycoprotein VI
|
Cardiovascular Disease
|
|
Batifiban TFA, a cyclic peptide, is an antagonist of platelet glycoprotein GPⅡb/Ⅲa and inhibits platelet aggregation. Batifiban blocks the binding of circulating vitronectin to integrin ανβ3 .
|
-
- HY-P1236
-
|
Atrial natriuretic factor (1-28) (rat, mouse)
|
Endothelin Receptor
|
Cardiovascular Disease
Endocrinology
|
|
Atrial Natriuretic Peptide (ANP) (1-28), rat, mouse is a major circulating form of ANP in rats, potently inhibits Angiotensin II (Ang II)-stimulated endothelin-1 secretion in a concentration-dependent manner.
|
-
- HY-P3954
-
|
|
Somatostatin Receptor
|
Metabolic Disease
|
|
Somatostatin-28 (sheep, human rat mouse) is a biologically active polypeptide, synthesised in the proximal intestinal epithelial cells. Somatostatin-28 (sheep, human rat mouse) suppresses glucose-stimulated insulin secretion without affecting circulating basal insulin concentration. Somatostatin-28 (sheep, human rat mouse) also targets to somatostatin receptor subtype 5 (SSTR5) to regulate GLP-1 secretion .
|
-
- HY-P1573
-
-
- HY-P1573A
-
-
- HY-P1236A
-
|
Atrial natriuretic factor (1-28) (rat, mouse) TFA
|
Endothelin Receptor
|
Cardiovascular Disease
Endocrinology
|
|
Atrial Natriuretic Peptide (ANP) (1-28), rat, mouse (TFA) is a major circulating form of ANP in rats, potently inhibits Angiotensin II (Ang II)-stimulated endothelin-1 secretion in a concentration-dependent manner.
|
-
- HY-P4063
-
|
|
Peptides
|
Metabolic Disease
|
|
Pegylated synthetic human c-peptide retains bioactivity comparable to that of natural (i.e. non-polyethylene glycolated) C-peptides and has a prolonged circulating residence time in plasma for use in diabetic peripheral neuropathy studies .
|
-
- HY-125053
-
|
|
Integrin
|
Cardiovascular Disease
|
|
Batifiban, a cyclic peptide, is a platelet glycoprotein GPⅡb/Ⅲa antagonist, and inhibits platelet aggregation. Batifiban blocks circulating vitronectin binding to integrin ανβ3, Batifiban can be used for research of acute coronary syndromes .
|
-
- HY-P10065
-
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99645
-
-
- HY-P99443
-
|
HuDreg-55
|
P-selectin
|
Inflammation/Immunology
|
|
Aselizumab (HuDreg-55) is an humanized IgG4 mAb against L-selectin. However, L-selectin (CD62L) is a cell adhesion molecule expressed on circulating neutrophils. It regulates migrating cells to chemotaxis towards the site of injury. Aselizumab may be account for a high rate of infections and leucopenia after truma .
|
-
- HY-P9930
-
|
AMG 145
|
NF-κB
Ser/Thr Protease
Toll-like Receptor (TLR)
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H2O2-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .
|
-
- HY-P99469
-
|
PB 2452; MEDI 2452
|
Inhibitory Antibodies
|
Metabolic Disease
|
|
Bentracimab (PB 2452) is a neutralizing monoclonal antibody that binds Ticagrelor (HY-1006) and its major active circulating metabolite with high affinity. Bentracimab can rapidly reverse the antiplatelet effect of Ticagrelor .
|
-
- HY-P99790
-
|
CEN 000029; cM-T412
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Priliximab (CEN 000029) is an anti-CD4 humanized monoclonal antibody. Priliximab binds to CD4 on the surface of T cells, resulting in a significant and sustained reduction in circulating CD4 + T cells. Priliximab can be used in research of rheumatoid arthritis (RA) .
|
-
- HY-163480
-
|
|
CXCR
|
Inflammation/Immunology
|
|
PF-06835375 is a humanized IgG1 antibody selective against CXCR5 expressed on B cells, Tfh cells, and circulating Tfh-like (cTfh) cells. PF-06835375 can be used for the study of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) [1].
|
-
- HY-P991073
-
|
|
Amyloid-β
|
Neurological Disease
|
|
MEDI-1814 is a fully human IgG1 antibody that targets the C terminus of Aβ42. MEDI-1814 binds to and sweeps away the circulated Aβ peptides, hence, restricting them from aggregating into toxic oligomers. MEDI-1814 can be used for the study of Alzheimer's diseases. The isotype control for MEDI-1814 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-113046
-
-
-
- HY-114297
-
-
-
- HY-113293B
-
-
-
- HY-N3021
-
|
|
Structural Classification
Natural Products
Classification of Application Fields
Source classification
Metabolic Disease
Endogenous metabolite
Disease Research Fields
|
Endogenous Metabolite
NF-κB
TNF Receptor
FOXO
Microtubule/Tubulin
|
|
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome .
|
-
-
- HY-113046R
-
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-70002AS
-
|
|
|
N-desmethyl Enzalutamide-d6 is a deuterium labeled N-desmethyl Enzalutamide. N-desmethyl Enzalutamide is an active metabolite of Enzalutamide. N-desmethyl Enzalutamide is the active metabolite of Enzalutamide. N-desmethyl Enzalutamide demonstrates primary and secondary pharmacodynamics of similar potency to Enzalutamide and circulates at approximately the same plasma concentrations as enzalutamide[1].
|
-
-
- HY-13332
-
|
|
|
Calcifediol-d6 is the deuterium labeled Calcifediol. Calcifediol, a major circulating metabolite of vitamin D3, is a potent VDR ligand .
|
-
-
- HY-113293BS1
-
|
|
|
Estrone sulfate-d4 (sodium) is deuterium labeled Estrone sulfate (sodium). Estrone sulfate, a biologically inactive form of estrogen, is a major circulating plasma estrogen that is converted into the biologically active estrogen, estrone (E1) by steroid sulfatase (STS). strone sulfate can be used for the research of breast cancer[1][2].
|
-
-
- HY-12753S
-
|
|
|
Debutyldronedarone-d7 is deuterium labeled Debutyldronedarone. Debutyldronedarone is a major circulating active metabolite of dronedarone (HY-A0016) in humans.Debutyldronedarone exhibits a potency that is 1/10 to 1/3 of that of the parent agent[1][2].
|
-
-
- HY-12753S1
-
|
|
|
Debutyldronedarone-d6 (hydrochloride) is deuterium labeled Debutyldronedarone. Debutyldronedarone is a major circulating active metabolite of dronedarone (HY-A0016) in humans. Debutyldronedarone exhibits a potency that is 1/10 to 1/3 of that of the parent agent[1][2].
|
-
-
- HY-113293BS
-
|
|
|
Estrone sulfate-d5 (sodium) is the deuterium labeled Estrone sulfate sodium. Estrone sulfate, a biologically inactive form of estrogen, is a major circulating plasma estrogen that is converted into the biologically active estrogen, estrone (E1) by steroid sulfatase (STS). strone sulfate can be used for the research of breast cancer[1][2].
|
-
-
- HY-135334S
-
|
|
|
ACP-5862-d4 is deuterium labeled ACP-5862. ACP-5862 is a major active, circulating, pyrrolidine ring-opened metabolite of Acalabrutinib with an IC50 of 5.0 nM for Bruton tyrosine kinase (BTK). ACP‐5862 is a weak time‐dependent inactivator of CYP3A4 and CYP2C8. Acalabrutinib is an orally active, irreversible, and highly selective BTK inhibitor, with an IC50 of 3 nM and EC50 of 8 nM[1][2].
|
-
-
- HY-113046S1
-
|
|
|
5-Methyltetrahydrofolic acid- 13C6 (5-Methyl THF- 13C6) is 13C labeled 5-Methyltetrahydrofolic acid. 5-Methyltetrahydrofolic acid (5-Methyl THF) is the main circulating form of folic acid in the body and is involved in a variety of biochemical reactions. 5-Methyltetrahydrofolic acid regulates cardiovascular function by increasing the production of endothelin-1 (ET-1) in low-density lipoprotein-treated endothelial cells and can be used in the study of cardiovascular diseases .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-W440831
-
|
|
|
Azide
|
|
DSPE-PEG-Azide, MW 1000 is a phospholipid with covalently attached polydisperse PEG. This polymer is commonly used for the preparation of long circulating liposomes. The azide moiety is reactive with alkyne to form a stable triazole bond. Reagent grade, for research use only.
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-148370A
-
|
RG6299 sodium
|
|
Antisense Oligonucleotides
|
|
IONIS-FB-LRx sodium is a specific antisense oligonucleotide (ASO) targeting complement factor B (CFB). IONIS-FB-LRx sodium effectively reduces circulating levels of CFB, and can be used for geographic atrophy (GA) research .
|
-
- HY-148370
-
|
RG6299
|
|
Antisense Oligonucleotides
|
|
IONIS-FB-LRx is a specific antisense oligonucleotide (ASO) targeting complement factor B (CFB). IONIS-FB-LRx effectively reduces circulating levels of CFB. IONIS-FB-LRx can be used for geographic atrophy (GA) research .
|
-
- HY-153485
-
|
ISIS 766720; IONIS-GHR-LRx
|
|
Antisense Oligonucleotides
|
|
Cimdelirsen is a novel, ligand-conjugated, hepatic-targeted investigative antisense oligonucleotide designed to reduce growth hormone receptor (GHr) synthesis, thereby inhibiting deleterious effects of growth hormone (GH) hypersecretion and reducing circulating insulin-like growth factor-1 (IGF-1) levels in acromegaly patients.
|
-
- HY-153485A
-
|
ISIS 766720 sodium; IONIS-GHR-LRx sodium
|
|
Antisense Oligonucleotides
|
|
Cimdelirsen is a novel, ligand-conjugated, hepatic-targeted investigative antisense oligonucleotide designed to reduce growth hormone receptor (GHr) synthesis, thereby inhibiting deleterious effects of growth hormone (GH) hypersecretion and reducing circulating insulin-like growth factor-1 (IGF-1) levels in acromegaly patients.
|
-
- HY-160066
-
|
|
|
Aptamers
|
|
SYL3C aptamer sodium is a DNA aptamer that targets the epithelial cell adhesion molecule (EpCAM) on the surface of cancer cells. SYL3C aptamer sodium targets multiple human cancer cell lines including MDA-MB-231, Kato III, HT-29, T47D and SW480. The Kd of SYL3C aptamer sodium against breast cancer cell line MDA-MB-231 and gastric cancer cell line Kato III is 38 nM and 67 nM, respectively. SYL3C aptamer sodium provides stability, high binding affinity, and selectivity for targeted cancer therapy, cancer cell imaging, and circulating tumor cell detection .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
